The mission of the Interbio work package 5 (WP5) consists in promoting and facilitating public-private partnerships across the 5 Interbio regions in the field of life and health sciences. Transferring the results of academic interdisciplinary research as well as making available the resources and expertise available in academic labs and technology platforms to the industry - particularly SMEs, start-ups and spin-offs – has been our on-going concern since the launch of the Interbio project.
Every Interbio partner has contributed in achieving the WP5 mission, resulting in the following actions:
IECB (Bordeaux) has elaborated and supervised the promotion of the Interbio technology offers on the Interbio website.
IECB (Bordeaux) has organized, together with the other Interbio node, the participation of Interbio researchers and technology platform representatives to the 2nd edition of the biotechnology and healthcare Euro-regional meeting, held in Montpellier on July 1-2 2010, where they were able to liaise with biotech companies as well as key industry players.
A white book entitled “Technology Transfer to Businesses” will be soon released by BIOCAT (Barcelona). It will provide companies with the keys to understand the technology transfer process and guidelines to negotiate licensing or collaborative agreements with Offices of Technology Transfer (OTT).
FIVEC (Valencia) is preparing the first Interbio Research-to-Business (R2B) meeting in Health Sciences and Technologies, which will be held on November17-18 2011 in Valencia. This event will bring together researchers, offices of technology transfer, technology platform representatives, biotech companies as well as key industry players from all the Interbio regions, through a format combining face-to-face meetings, oral presentations and roundtables.
All these actions, initially planned in the Interbio project, will be completed before the end of 2011. They will all contribute to the emergence of collaborations between academic laboratories, technology platforms and companies.
Coordinator of the Interbio GT5
Chief Executive Officer at Cancer-Bio-Santé Cluster